WO2005033089A1 - Sel d'acide 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoique avec du diamide de n, n-dimethyl-imidodicarbonimidique - Google Patents
Sel d'acide 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoique avec du diamide de n, n-dimethyl-imidodicarbonimidique Download PDFInfo
- Publication number
- WO2005033089A1 WO2005033089A1 PCT/IN2003/000329 IN0300329W WO2005033089A1 WO 2005033089 A1 WO2005033089 A1 WO 2005033089A1 IN 0300329 W IN0300329 W IN 0300329W WO 2005033089 A1 WO2005033089 A1 WO 2005033089A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- isobenzofuranyl
- dihydro
- oxo
- methoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Definitions
- 6-(l,3 ⁇ dihydro-4-hydroxy-6-methoxy-7-methyl-3- oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid, sodium salt or its 2-ethyl morphoiino derivative is used as immunosuppressants.
- 6- (l,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4-methyl-4-hexenoic acid is generally administered as a sodium salt or 2-ethyl morphoiino derivative so that active free acid is made available for absorption.
- Antihyperglycemic agents are used for treatment of diabetes.
- N, N- dimethyl- imidodicarbonimidic diamide is used for treatment of Non-insulin dependent diabetes mellitus (NIDDM).
- N, N-dimethyl- imidodicarbonimidic diamide is generally administered a HCI salt.
- the present inventions discloses a novel compound of formula I which can be simultaneously used as an immunosuppressant and antihyperglycemic agent for the treatment of diabetic nephropathy.
- SUMMARY OF THE INVENTION The present invention discloses a novel compound of formula I. The compound can be simultaneously used as an immunosuppressant and antihyperglycemic agent for the treatment of diabetic nephropathy.
- FORMULA I The important embodiment of the invention is that the compound of formula I, wherein the two drug molecules form a mutual salt which can be called X N, N-dimethyl- imidodicarbonimidic diamide salt of 6-(l,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3- oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid.
- the invention discloses the compound of formula I, wherein the 6-(l,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4-methyl-4-hexenoic acid is an immunosuppressive drug and N, N-dimethyl- imidodicarbonimidic diamide is an antihyperglycemic drug.
- the compound of formula I is formed when the two compounds are treated with each other under suitable conditions to form a non-covalent bond between the carboxylic group of 6- (l,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4-methyl-4-hexenoic acid and nitrogen of N, N- dimethyl- imidodicarbonimidic diamide.
- the non- covalent bond thus formed is an ionic bond between 6-(l,3- dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)- 4-methyl-4-hexenoic acid and N, N-dimethyl- imidodicarbonimidic diamide.
- the compound of formula I is a mutual salt of 6-(l,3- dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)- 4-methyl-4-hexenoic acid and N, N-dimethyl- imidodicarbonimidic diamide.
- compound of formula I retain the free acid form of 6-(l,3-dihydro- 4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl- 4-hexenoic acid.
- Compound of formula I have the extra advantage of delivering the free acid form of 6-( ⁇ ,3-dihydro-4-hydroxy-6- methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid without employing any metal cation. Unlike prior art, compound of formula I delivers N, N- dimethyl- imidodicarbonimidic diamide free-base without employing any other acid salt like hydrochloride salt.
- the following non-limiting examples illustrate the inventors' preferred method for preparing the compound of the invention.
- reaction mixture was chilled (10-15° C) and filtered to afford the mutual salt of 6-(l,3-dihydro-4-hydroxy-6- methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic5 acid and N, N-dimethyl- imidodicarbonimidic diamide.
- Example 2 To a solution of 6-(l,3-dihydro-4-hydroxy-6-methoxy-7- methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid (10 g, 0.03 mol) in isobutyl acetate (75 ml), N, N-dimethyl-o imidodicarbonimidic diamide free base (4.0 g, 0.03 mol) was added and stirred.
- reaction mixture was chilled (10-15° C) and filtered o afford the mutual salt of 6-(l,3-dihydro-4-hydroxy-6-methoxy-7- methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid and N, N-dimethyl- imidodicarbonimidic diamide.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2003/000329 WO2005033089A1 (fr) | 2003-10-07 | 2003-10-07 | Sel d'acide 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoique avec du diamide de n, n-dimethyl-imidodicarbonimidique |
AU2003272083A AU2003272083A1 (en) | 2003-10-07 | 2003-10-07 | Salt of 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid with n, n-dimethyl-imidodicarbonimidic diamide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2003/000329 WO2005033089A1 (fr) | 2003-10-07 | 2003-10-07 | Sel d'acide 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoique avec du diamide de n, n-dimethyl-imidodicarbonimidique |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005033089A1 true WO2005033089A1 (fr) | 2005-04-14 |
Family
ID=34401267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2003/000329 WO2005033089A1 (fr) | 2003-10-07 | 2003-10-07 | Sel d'acide 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoique avec du diamide de n, n-dimethyl-imidodicarbonimidique |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003272083A1 (fr) |
WO (1) | WO2005033089A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008003637A2 (fr) * | 2006-07-05 | 2008-01-10 | Dsm Ip Assets B.V. | Isolation et utilisation de sels aminés d'acide mycophénolique |
US7683188B2 (en) | 2004-04-26 | 2010-03-23 | TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság | Process for preparation of mycophenolic acid and ester derivatives thereof |
WO2010146604A2 (fr) | 2009-06-18 | 2010-12-23 | Exemed Pharmaceuticals | Procédés de préparation de chlorhydrate de metformine |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4948793A (en) * | 1987-01-30 | 1990-08-14 | Syntex (U.S.A.) Inc. | Treatment of autoimmune diseases with the morpholinoethyl ester of mycophenolic acid, and derivatives thereof |
WO2003011273A1 (fr) * | 2001-07-31 | 2003-02-13 | The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Metformine utilisee dans le traitement de conditions hyperglycemiques |
-
2003
- 2003-10-07 WO PCT/IN2003/000329 patent/WO2005033089A1/fr active Application Filing
- 2003-10-07 AU AU2003272083A patent/AU2003272083A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4948793A (en) * | 1987-01-30 | 1990-08-14 | Syntex (U.S.A.) Inc. | Treatment of autoimmune diseases with the morpholinoethyl ester of mycophenolic acid, and derivatives thereof |
WO2003011273A1 (fr) * | 2001-07-31 | 2003-02-13 | The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Metformine utilisee dans le traitement de conditions hyperglycemiques |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7683188B2 (en) | 2004-04-26 | 2010-03-23 | TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság | Process for preparation of mycophenolic acid and ester derivatives thereof |
WO2008003637A2 (fr) * | 2006-07-05 | 2008-01-10 | Dsm Ip Assets B.V. | Isolation et utilisation de sels aminés d'acide mycophénolique |
WO2008003637A3 (fr) * | 2006-07-05 | 2008-05-08 | Dsm Ip Assets Bv | Isolation et utilisation de sels aminés d'acide mycophénolique |
WO2010146604A2 (fr) | 2009-06-18 | 2010-12-23 | Exemed Pharmaceuticals | Procédés de préparation de chlorhydrate de metformine |
Also Published As
Publication number | Publication date |
---|---|
AU2003272083A1 (en) | 2005-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7638627B2 (en) | Process of preparing imatinib and imatinib prepared thereby | |
US11622942B2 (en) | Benzene-1,3,5-tricarboxamide derived ester lipids and uses thereof | |
US11718611B2 (en) | Benzenesulfonylbenazamide compound for inhibiting BCL-2 protein and composition and use thereof | |
US7803942B2 (en) | Crystals of morphinan derivative and process for producing the same | |
WO2010146604A2 (fr) | Procédés de préparation de chlorhydrate de metformine | |
US20080045707A1 (en) | Processes for the preparation of linezolid intermediate | |
EP2625162A1 (fr) | Procédés de fabrication d'acétate de phényle de l-ornithine | |
WO2005023766A1 (fr) | Sel d'atorvastatine associee a de la metformine | |
US8153672B2 (en) | Polymorphic forms of deferasirox (ICL670A) | |
US6531509B2 (en) | Stable gabapentin containing more than 20 ppm of chlorine ion | |
US20040147607A1 (en) | Stable gabapentin having pH within a controlled range | |
AU2001266992A1 (en) | Stable gabapentin having pH within a controlled range | |
WO2005033089A1 (fr) | Sel d'acide 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoique avec du diamide de n, n-dimethyl-imidodicarbonimidique | |
CN115461344A (zh) | 一种glp-1受体激动剂的晶型a及其制备方法 | |
WO2006086773A2 (fr) | Analogues de polyamine en tant que modulateurs de la migration cellulaire et de la motilite cellulaire | |
WO2005033067A1 (fr) | Sel de l'acide 1,2,6,7,8,8a-hexahydro-?,?,6-trihydroxy-2-methyl-8-[(2s)-2-methyl-1-oxobutoxy]-, (?r,? r,1s,2s,6s,8s,8ar)- 1-naphthaleneheptanoique et d'un diamide n,n-dimethyl-imidodicarbonimidique | |
US20100069443A1 (en) | Compound with benzamide skeleton having cyclooxygenase-1 (cox-1)-selective inhibitory activity | |
AU2019349414B2 (en) | Process for preparing the compound 2,2-difluoro-N-((1R,2S)-3-fluoro-1-hydroxy-1-(4-(6-(S-methylsulfonimidoyl)pyridin-3-yl)phenyl)propan-2-yl)acetamide | |
RU2389491C2 (ru) | Комплекс, содержащий меквитазин (mequitazine), циклодекстрин и агент взаимодействия | |
US10081605B2 (en) | Synthesis of cyclocreatine and analogs thereof | |
JPS63255268A (ja) | ドーパミン−β−ヒドロキシラーゼ抑制剤 | |
KR101653816B1 (ko) | 결정형 사포그릴레이트 옥살산염 일수화물 또는 이의 무수물 | |
CN1489578A (zh) | 3-(3-脒苯基)-5-[({[1-(1-亚氨基乙基)-4-哌啶基]甲基}氨基)甲基]苯甲酸二盐酸盐及其制备方法 | |
KR860000999B1 (ko) | N(2,6-디클로로페닐)아세트아미딘의 제조방법 | |
CA2859156A1 (fr) | Traitement du diabete de type i et de type ii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |